| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 International Agency for Research on Cancer, Lyon, France; 2 GlaxoSmithKline R&D, Middlesex, United Kingdom; and 3 University of North Carolina, Chapel Hill, North Carolina
Requests for reprints: Gary M. Clifford, IARC, 150 Cours Albert Thomas, F-69372 Lyon cedex 08, France. Phone: 33-4-72-73-84-25; Fax: 33-4-72-73-83-45. E-mail: clifford{at}iarc.fr
Low-grade squamous intraepithelial lesions (LSIL) associated with certain human papillomavirus (HPV) genotypes may preferentially progress to cervical cancer. HPV genotyping may thus have the potential to improve the effectiveness of screening programs and to reduce overtreatment. LSIL cases (n = 8,308) from 55 published studies were included in a meta-analysis. HPV genotype distribution was assessed by geographic region and in comparison with published data on cervical squamous cell carcinoma (SCC). HPV detection in LSIL was 80% in North America but less than 70% in other regions, most likely reflecting regional differences in LSIL diagnosis. Among 5,910 HPV-positive LSILs, HPV16 was the most common genotype (26.3%) followed by HPV31 (11.5%), HPV51 (10.6%), and HPV53 (10.2%). HPV-positive LSILs from Africa were 2-fold less likely to be infected with HPV16 than those in Europe, and HPV-positive LSILs from North America were more likely to be infected with HPV18 than those from Europe or South/Central America. Interpretation for rarer genotypes was hampered by variation in HPV testing methodology. SCC/LSIL prevalence ratios indicated that HPV16 was 2-fold and HPV18 was 1.5-fold more common in SCC than in HPV-positive LSIL, thus appearing more likely to progress than other high-risk genotypes (SCC/LSIL prevalence ratios between 0.05 and 0.85). HPV53 and HPV66 showed SCC/LSIL ratios of 0.02 and 0.01, respectively. HPV genotype distribution in LSIL differs from that in cervical cancer, highlighting the importance of HPV genotype in the risk of progression from LSIL to malignancy. Some regional differences in the relative importance of HPV genotypes in LSIL were noted.
This article has been cited by other articles:
|
|
 |
|
  D. Grisaru, B. Avidor, J. Niv, S. Marmor, B. Almog, C. Leibowitz, M. Graidy, and M. Giladi Pilot Study of Prevalence of High-Risk Human Papillomavirus Genotypes in Israeli Jewish Women Referred for Colposcopic Examination J. Clin. Microbiol., May 1, 2008; 46(5): 1602 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishiwaki, T. Yamamoto, S. Tone, T. Murai, T. Ohkawara, T. Matsunami, M. Koizumi, Y. Takagi, J. Yamaguchi, N. Kondo, et al. Genotyping of Human Papillomaviruses by a Novel One-Step Typing Method with Multiplex PCR and Clinical Applications J. Clin. Microbiol., April 1, 2008; 46(4): 1161 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gorander, T. Lagergard, M. Romanik, R. P. Viscidi, G. Martirosian, and J.-A. Liljeqvist Seroprevalences of Herpes Simplex Virus Type 2, Five Oncogenic Human Papillomaviruses, and Chlamydia trachomatis in Katowice, Poland Clin. Vaccine Immunol., April 1, 2008; 15(4): 675 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steben Do you approve of spending $300 million on HPV vaccination?: YES Can Fam Physician, February 1, 2008; 54(2): 174 - 176. [Full Text] [PDF]
|
|
|
|
|
|
M. Steben Approuvez-vous les 300 M $ pour la vaccination contre le VPH?: OUI Can Fam Physician, February 1, 2008; 54(2): 178 - 180. [Full Text] [PDF]
|
|
|
|
 |
|
 Y P Bao, N Li, J S Smith, and Y L Qiao Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis Int J STD AIDS, February 1, 2008; 19(2): 106 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Yu, A. Bashirova, M. M. Madeleine, J. Cheng, L. G. Johnson, S. M. Schwartz, M. Carrington, and A. Hildesheim Evaluation of the Association with Cervical Cancer of Polymorphisms in Syndecan-1, a Heparan Sulfate Proteoglycan Involved with Viral Cell Entry Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2504 - 2508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Coutlee, D. Rouleau, G. Ghattas, C. Hankins, S. Vezina, P. Cote, J. Macleod, A. de Pokomandy, D. Money, S. Walmsley, et al. Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test J. Clin. Microbiol., November 1, 2007; 45(11): 3821 - 3823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kim, K. M. Kuntz, N. K. Stout, S. Mahmud, L. L. Villa, E. L. Franco, and S. J. Goldie Multiparameter Calibration of a Natural History Model of Cervical Cancer Am. J. Epidemiol., July 15, 2007; 166(2): 137 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Chan and J. S. Berek Impact of the Human Papilloma Vaccine on Cervical Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2975 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Huh, J. E. Kendrick, and R. D. Alvarez New Advances in Vaccine Technology and Improved Cervical Cancer Prevention Obstet. Gynecol., May 1, 2007; 109(5): 1187 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Halfon, E. Trepo, G. Antoniotti, C. Bernot, P. Cart-Lamy, H. Khiri, D. Thibaud, J. Marron, A. Martineau, G. Penaranda, et al. Prospective Evaluation of the Hybrid Capture 2 and AMPLICOR Human Papillomavirus (HPV) Tests for Detection of 13 High-Risk HPV Genotypes in Atypical Squamous Cells of Uncertain Significance J. Clin. Microbiol., February 1, 2007; 45(2): 313 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Schiller and D. R. Lowy Prospects for Cervical Cancer Prevention by Human Papillomavirus Vaccination Cancer Res., November 1, 2006; 66(21): 10229 - 10232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Mao, L. A. Koutsky, K. A. Ault, C. M. Wheeler, D. R. Brown, D. J. Wiley, F. B. Alvarez, O. M. Bautista, K. U. Jansen, E. Barr, et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial Obstet. Gynecol., January 1, 2006; 107(1): 18 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Franceschi and G. M. Clifford Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests J Natl Cancer Inst, June 15, 2005; 97(12): 938 - 939. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
